Protara Therapeutics, Inc.
NGM: TARALive Quote
📈 ZcoreAI Score
Our AI model analyzes Protara Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get TARA Z-Score →About Protara Therapeutics, Inc.
Healthcare
Biotechnology
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
📊 Fundamental Analysis
Protara Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -31.6%, which indicates that capital utilization is currently under pressure.
At a current price of $4.96, TARA currently sits at the 43rd percentile of its 52-week range (Range: $2.77 - $7.82).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$268.26M
Trailing P/E
--
Forward P/E
-3.57
Beta (5Y)
1.50
52W High
$7.82
52W Low
$2.77
Avg Volume
1.05M
Day High
Day Low